Chiang Kyle 4
4 · LogicBio Therapeutics, Inc. · Filed Apr 19, 2021
Insider Transaction Report
Form 4
Chiang Kyle
Chief Operating Officer
Transactions
- Sale
Common Stock
2021-04-16$5.73/sh−2,977$17,058→ 23,387 total - Exercise/Conversion
Common Stock
2021-04-15+9,360→ 26,364 total - Exercise/Conversion
Restricted Stock Units
2021-04-15−9,360→ 0 total→ Common Stock (9,360 underlying)
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represented a contingent right to receive one share of common stock of LogicBio Therapeutics, Inc. (the "Company").
- [F2]Relates to shares sold at a weighted average price of $5.73 per share to cover tax withholding obligations in connection with the vesting of RSUs. Shares were sold in multiple transactions at prices ranging from $5.68 to $5.89, inclusive. The reporting person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]All of the RSUs vested on April 15, 2021, subject to the terms and conditions of the award and the Company's 2018 Equity Incentive Plan.